# A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

> **NCT02700022** · PHASE1 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Burkitt Lymphoma

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT02700022
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2016-11-15
- **Final completion:** 2017-08-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2017-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700022, "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02700022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*